These results suggest that the phosphorylation of XIAP by AKT induces resistance to AZD5582, and further indicates that the phosphorylation of both AKT and XIAP in human pancreatic cancer may be a predictive biomarker for the efficacy of AZD5582 treatment. This evidence concerns the gene AKT1 and pancreatic neoplasm.